Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30.7Revenue $M0.1Net Margin (%)-8,583.9Z-Score-41.0
Enterprise Value $M32.7EPS $-0.9Operating Margin %-7,650.6F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-8,700.0Higher ROA y-yN
Price/Book23.910-y EBITDA Growth Rate %-20.4Quick Ratio0.8Cash flow > EarningsY
Price/Sales4195-y EBITDA Growth Rate %-42.7Current Ratio0.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-116.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-216.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M6.7ROI % (ttm)-22.5Gross Margin Increase y-yN

Gurus Latest Trades with NVGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVGNRonald Muhlenkamp 2013-03-31 Sold Out -0.03%$1.84 - $9.05
($3.83)
$ 4.5516%Sold Out0
NVGNRonald Muhlenkamp 2012-12-31 Reduce-0.01%$1.5 - $10.24
($4.96)
$ 4.55-9%Reduce -49.15%18,184
NVGNRonald Muhlenkamp 2012-06-30 Buy 0.02%$1.95 - $2.5
($2.26)
$ 4.5550%New holding35,757
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVGN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NVGN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVGN :

    Quarterly/Annual Reports about NVGN:

      News about NVGN:

      Articles On GuruFocus.com
      Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 
      comment on NVGN Mar 06 2013 

      More From Other Websites
      Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study Mar 18 2015
      Sky News, Helen Dalley interviews Dr Graham Kelly Mar 09 2015
      Cantrixil Data to be Presented at Two Major Conferences Mar 06 2015
      Novogen Makes Big Step In Fighting Brain Cancer Mar 04 2015
      US Studies Confirm Ability of TRXE-009 to Kill Brain Cancer Stem Cells Mar 04 2015
      Novogen to Present at AusBiotech "Broker Meets Biotech" Event Mar 02 2015
      Novogen to Present at SACHS Cancer Bio Partnering & Investment Forum Feb 22 2015
      Novogen Investor Briefing Well Received Feb 19 2015
      Novogen Lodges Key Super-benzopyran Patent Feb 11 2015
      Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015 Feb 03 2015
      Novogen Soars 50% Following Brain Stem Cell News Jan 15 2015
      Novogen Announces Important Discovery in Regenerative Medicine Program Jan 15 2015
      Novogen to Conduct Shareholder/Investor Briefing in New York Jan 07 2015
      Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private... Dec 19 2014
      Novogen Raises A$4.1m In Private Placement to US Institutions Dec 17 2014
      Novogen Announces Breakthrough Discovery in the Treatment of Melanoma Dec 16 2014
      Novogen Shares Skyrocket 120% Following Drug News Dec 16 2014
      Novogen Provides Update On Progress Of Cantrixil Into The Clinic Dec 15 2014
      ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer Sep 29 2014
      Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference Sep 03 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK